Intensity Therapeutics (INTS) Amortizatization of Intangibles (2022 - 2023)
Intensity Therapeutics' (INTS) quarterly Amortizatization of Intangibles came in at $146000.0 in Q2 2023, up 1023.08% on a QoQ basis from $13000.0 in Q1 2023.
Intensity Therapeutics (INTS) Amortizatization of Intangibles (2022 - 2023) Analysis & Trends
Intensity Therapeutics (INTS) has 2 years of Amortizatization of Intangibles data on file, last reported at $146000.0 in Q2 2023.
- Quarterly Amortizatization of Intangibles changed N/A year-over-year to $146000.0 in Q2 2023, while the trailing twelve-month figure through Mar 2024 was $146000.0 (changed N/A YoY) and the FY2023 annual result came in at $159000.0, changed N/A from the prior year.
- Amortizatization of Intangibles climbed to $146000.0 in Q2 2023, from $13000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $146000.0 in Q2 2023 to a low of -$133605.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Intensity Therapeutics | 12.99 Mn | 12.99 Mn | - | 7,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 146,000.00 |
| Jun 30, 2023 | 146,000.00 |
| Mar 31, 2023 | 13,000.00 |
| Mar 31, 2023 | 13,000.00 |
| Dec 31, 2022 | -133,605.00 |
| Dec 31, 2022 | -133,605.00 |
| Sep 30, 2022 | 44,977.00 |
| Sep 30, 2022 | 44,977.00 |